chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 31.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Full blood count normal, Gingival bleeding, Heavy menstrual bleeding, Immunoglobulin therapy, Iron deficiency
Clinical narrative: PMHx of gestational DM presented to the ED on 3/6/21 with black spots on tongue and sides of mouth in addition to gum bleeding all that started suddenly on Friday night, 03/05/21.  She also noted a petechial rash on her chest, face, and abdomen.  She has no history of this in the past, nor prior bleeding events.  She has had 2 deliveries without abnormal bleeding.  She did receive the first dose of her Moderna vaccine on 2/24/21.  She also started having menstrual period on 02/26 which were heavier than usual for past 2 days then became more regular. Her periods usually last 7-8 days.   Platelets were 3K on admission.  She denies any recent infection or new medications.  She felt very well preceding this event.  She did not have any other reactions from the Moderna vaccine.  A recent cbc on 1/11/21 was completely normal with a platelet count of 238K.   3/6/21 CBC on admission:  10.2>13.6<3k No other CBC with diff abnormalities DIC labs are negative; Hemolysis labs are negative. She is noted to have iron deficiency In the ED she was given 4 units of platelets. She was started on 40mg po daily Decadron on 3/6/21.  3/7/21 plts rose to 8K;  Black spots and petechiae significantly decreased, 3/8/21 plts rose to 54K; Patient clinically stable. 3/9/21 plts rose to 84K 3/23/21 plts 201K patient was treated with dexamethasone and IVIG
Age: 31.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Petechiae, Platelet count abnormal, Platelet count decreased, Platelet transfusion, Tongue discolouration
Clinical narrative: PMHx of gestational DM presented to the ED on 3/6/21 with black spots on tongue and sides of mouth in addition to gum bleeding all that started suddenly on Friday night, 03/05/21.  She also noted a petechial rash on her chest, face, and abdomen.  She has no history of this in the past, nor prior bleeding events.  She has had 2 deliveries without abnormal bleeding.  She did receive the first dose of her Moderna vaccine on 2/24/21.  She also started having menstrual period on 02/26 which were heavier than usual for past 2 days then became more regular. Her periods usually last 7-8 days.   Platelets were 3K on admission.  She denies any recent infection or new medications.  She felt very well preceding this event.  She did not have any other reactions from the Moderna vaccine.  A recent cbc on 1/11/21 was completely normal with a platelet count of 238K.   3/6/21 CBC on admission:  10.2>13.6<3k No other CBC with diff abnormalities DIC labs are negative; Hemolysis labs are negative. She is noted to have iron deficiency In the ED she was given 4 units of platelets. She was started on 40mg po daily Decadron on 3/6/21.  3/7/21 plts rose to 8K;  Black spots and petechiae significantly decreased, 3/8/21 plts rose to 54K; Patient clinically stable. 3/9/21 plts rose to 84K 3/23/21 plts 201K patient was treated with dexamethasone and IVIG
Age: 31.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Full blood count, Platelet count, Thrombocytopenia
Clinical narrative: PMHx of gestational DM presented to the ED on 3/6/21 with black spots on tongue and sides of mouth in addition to gum bleeding all that started suddenly on Friday night, 03/05/21.  She also noted a petechial rash on her chest, face, and abdomen.  She has no history of this in the past, nor prior bleeding events.  She has had 2 deliveries without abnormal bleeding.  She did receive the first dose of her Moderna vaccine on 2/24/21.  She also started having menstrual period on 02/26 which were heavier than usual for past 2 days then became more regular. Her periods usually last 7-8 days.   Platelets were 3K on admission.  She denies any recent infection or new medications.  She felt very well preceding this event.  She did not have any other reactions from the Moderna vaccine.  A recent cbc on 1/11/21 was completely normal with a platelet count of 238K.   3/6/21 CBC on admission:  10.2>13.6<3k No other CBC with diff abnormalities DIC labs are negative; Hemolysis labs are negative. She is noted to have iron deficiency In the ED she was given 4 units of platelets. She was started on 40mg po daily Decadron on 3/6/21.  3/7/21 plts rose to 8K;  Black spots and petechiae significantly decreased, 3/8/21 plts rose to 54K; Patient clinically stable. 3/9/21 plts rose to 84K 3/23/21 plts 201K patient was treated with dexamethasone and IVIG
Age: 44.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Headache, Nausea, Pain, Pain in extremity
Clinical narrative: Sudden high-blood pressure (potential heart issues) that did not exist prior to vaccine.
Age: 44.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Hypertension
Clinical narrative: Sudden high-blood pressure (potential heart issues) that did not exist prior to vaccine.
Age: 51.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Asthenia, CSF glucose increased, CSF protein increased, CSF red blood cell count positive, CSF white blood cell count increased
Clinical narrative: Patient received first dose of Moderna vaccine after which he immediately experienced weakness, myalgias, fatigue.  Progressive weakness in limbs continued and by day 13 following his vaccine patient presented to hospital with difficulty speaking and inability to walk.  Admitted to acute care hospital for progressive extremity weakness, bulbar weakness, and respiratory failure.  EMG testing demonstrated findings of demyelinating neuropathy.  Patient transferred 3/31/21 for intensive inpatient rehabilitation and remains currently hospitalized.
Age: 51.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Guillain-Barre syndrome, Lumbar puncture
Clinical narrative: Patient received first dose of Moderna vaccine after which he immediately experienced weakness, myalgias, fatigue.  Progressive weakness in limbs continued and by day 13 following his vaccine patient presented to hospital with difficulty speaking and inability to walk.  Admitted to acute care hospital for progressive extremity weakness, bulbar weakness, and respiratory failure.  EMG testing demonstrated findings of demyelinating neuropathy.  Patient transferred 3/31/21 for intensive inpatient rehabilitation and remains currently hospitalized.
Age: 51.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Asthenia, Demyelinating polyneuropathy, Electromyogram abnormal, Fatigue, Gait inability
Clinical narrative: Patient received first dose of Moderna vaccine after which he immediately experienced weakness, myalgias, fatigue.  Progressive weakness in limbs continued and by day 13 following his vaccine patient presented to hospital with difficulty speaking and inability to walk.  Admitted to acute care hospital for progressive extremity weakness, bulbar weakness, and respiratory failure.  EMG testing demonstrated findings of demyelinating neuropathy.  Patient transferred 3/31/21 for intensive inpatient rehabilitation and remains currently hospitalized.
Age: 51.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Muscular weakness, Myalgia, Respiratory failure, Speech disorder
Clinical narrative: Patient received first dose of Moderna vaccine after which he immediately experienced weakness, myalgias, fatigue.  Progressive weakness in limbs continued and by day 13 following his vaccine patient presented to hospital with difficulty speaking and inability to walk.  Admitted to acute care hospital for progressive extremity weakness, bulbar weakness, and respiratory failure.  EMG testing demonstrated findings of demyelinating neuropathy.  Patient transferred 3/31/21 for intensive inpatient rehabilitation and remains currently hospitalized.
Age: 51.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Acute respiratory failure, Asthenia, Bulbar palsy, Demyelinating polyneuropathy, Electromyogram
Clinical narrative: Patient received first dose of Moderna vaccine after which he immediately experienced weakness, myalgias, fatigue.  Progressive weakness in limbs continued and by day 13 following his vaccine patient presented to hospital with difficulty speaking and inability to walk.  Admitted to acute care hospital for progressive extremity weakness, bulbar weakness, and respiratory failure.  EMG testing demonstrated findings of demyelinating neuropathy.  Patient transferred 3/31/21 for intensive inpatient rehabilitation and remains currently hospitalized.
Age: 51.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Gait disturbance, Ileus paralytic, Muscular weakness, Pneumonia, Respiratory failure
Clinical narrative: Patient received first dose of Moderna vaccine after which he immediately experienced weakness, myalgias, fatigue.  Progressive weakness in limbs continued and by day 13 following his vaccine patient presented to hospital with difficulty speaking and inability to walk.  Admitted to acute care hospital for progressive extremity weakness, bulbar weakness, and respiratory failure.  EMG testing demonstrated findings of demyelinating neuropathy.  Patient transferred 3/31/21 for intensive inpatient rehabilitation and remains currently hospitalized.
Age: 51.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: SARS-CoV-2 test
Clinical narrative: Patient received first dose of Moderna vaccine after which he immediately experienced weakness, myalgias, fatigue.  Progressive weakness in limbs continued and by day 13 following his vaccine patient presented to hospital with difficulty speaking and inability to walk.  Admitted to acute care hospital for progressive extremity weakness, bulbar weakness, and respiratory failure.  EMG testing demonstrated findings of demyelinating neuropathy.  Patient transferred 3/31/21 for intensive inpatient rehabilitation and remains currently hospitalized.
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Dizziness, Dyspnoea
Clinical narrative: Lymph node pain; This is a spontaneous report received from a contactable consumer (patient) reported for herself. A 46-years-old female patient received bnt162b2 (BNT162B2), dose 2 via an unspecified route of administration, administered in Arm Left on an unspecified date (Batch/Lot Number: EN6198) as SINGLE DOSE for covid-19 immunisation.  Historical vaccine included first dose of BNT162B2 (Batch/lot number: EL9261) on 05Feb2021 and experienced Injection site pain, Headache, Upper respiratory allergy symptoms, Shortness of breath, Chest pain, Chest tightness, Dizziness, Fatigue, Passed out, COVID induced POTS, Nausea, Throwing up, her husband thought she was having a stroke because she could not talk, I could not move, she could not breathe. The patient's medical history and concomitant medications were not reported.  The patient experienced lymph node pain on an unspecified date with outcome of unknown. Consumer stated: EN6198. That one also gave her lymph node pain. The new symptom she had from second one was lymph node pain. She had new symptoms after the second dose. She lost her job a couple of weeks later. She lost 10 days of her work and she was not able to work for about a month.  No follow-up attempts are needed. No further information is expected.
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Lymph node pain
Clinical narrative: Lymph node pain; This is a spontaneous report received from a contactable consumer (patient) reported for herself. A 46-years-old female patient received bnt162b2 (BNT162B2), dose 2 via an unspecified route of administration, administered in Arm Left on an unspecified date (Batch/Lot Number: EN6198) as SINGLE DOSE for covid-19 immunisation.  Historical vaccine included first dose of BNT162B2 (Batch/lot number: EL9261) on 05Feb2021 and experienced Injection site pain, Headache, Upper respiratory allergy symptoms, Shortness of breath, Chest pain, Chest tightness, Dizziness, Fatigue, Passed out, COVID induced POTS, Nausea, Throwing up, her husband thought she was having a stroke because she could not talk, I could not move, she could not breathe. The patient's medical history and concomitant medications were not reported.  The patient experienced lymph node pain on an unspecified date with outcome of unknown. Consumer stated: EN6198. That one also gave her lymph node pain. The new symptom she had from second one was lymph node pain. She had new symptoms after the second dose. She lost her job a couple of weeks later. She lost 10 days of her work and she was not able to work for about a month.  No follow-up attempts are needed. No further information is expected.
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Fatigue, Headache, Myalgia, Pain, Pyrexia
Clinical narrative: It turns out I was positive for COVID; It turns out I was positive for COVID; Was sick for about 3 weeks with Pneumonia; I become really sick with all the side effects; This is a spontaneous report from a contactable consumer (patient).   A 30-year-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as 1st dose, single for covid-19 immunisation.  The patient medical history and concomitant medications were not reported.  The patient became really sick with all the side effects the night after receiving his first Pfizer vaccine. It turns out he was positive for COVID at the same time he was sick for about 3 weeks with pneumonia. The events outcome was unknown.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Sex: M
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Drug ineffective, Illness, Pneumonia, SARS-CoV-2 test
Clinical narrative: It turns out I was positive for COVID; It turns out I was positive for COVID; Was sick for about 3 weeks with Pneumonia; I become really sick with all the side effects; This is a spontaneous report from a contactable consumer (patient).   A 30-year-old male patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as 1st dose, single for covid-19 immunisation.  The patient medical history and concomitant medications were not reported.  The patient became really sick with all the side effects the night after receiving his first Pfizer vaccine. It turns out he was positive for COVID at the same time he was sick for about 3 weeks with pneumonia. The events outcome was unknown.   No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Age: 48.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Condition aggravated, Emotional distress, Tinnitus
Clinical narrative: Tinnitus; it's a whooshing sound; Audiology for my hearing, is the one to check for my lost hearing; This is a spontaneous report from a contactable consumer (patient). A 48-year-old male patient (Height: 5'10 (unit not probed further), Weight: 220 (unit not probed further)) received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot Number: EN6203), via an unspecified route of administration, administered in Left Arm on 09Mar2021 (at the age of 48-year-old) at single dose for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient reported that he took the vaccine on 09Mar2021 and immediately he got the same day, he got the severe tinnitus in his ears and he was six weeks out and this been a lot, reading about it now. But, the tinnitus was really not gone away, it's a whooshing sound, it's really miserable, it's turned up on the day he got the Pfizer vaccine. He saw his ear, nose and throat doctor. His ENT doctor advised him surprisingly based on these other patients that came with same symptoms as him advised to skip the second vaccine. Patient didn't really want to skip the second dose, but he was at the 42 days and he want to wait for his tinnitus to get lower before getting it. Patient don't know what to do if he waited had 42 days there was no research, he would still like could get it his ears heel or if the tinnitus got lower. Patient had the severe tinnitus from the day he got the vaccine and he was now getting the 42 days maximum gap between doses. The patient underwent lab test and procedure which included Audiology for his hearing, was the one to check for his lost hearing: tinnitus from the vaccine on 24Mar2021. No treatment was received for the event. The outcome of the event was not recovered.  No follow-up attempts are needed. No further information is expected.
Age: 48.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Acoustic stimulation tests, Body height, Hypoacusis, Tinnitus, Weight
Clinical narrative: Tinnitus; it's a whooshing sound; Audiology for my hearing, is the one to check for my lost hearing; This is a spontaneous report from a contactable consumer (patient). A 48-year-old male patient (Height: 5'10 (unit not probed further), Weight: 220 (unit not probed further)) received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot Number: EN6203), via an unspecified route of administration, administered in Left Arm on 09Mar2021 (at the age of 48-year-old) at single dose for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient reported that he took the vaccine on 09Mar2021 and immediately he got the same day, he got the severe tinnitus in his ears and he was six weeks out and this been a lot, reading about it now. But, the tinnitus was really not gone away, it's a whooshing sound, it's really miserable, it's turned up on the day he got the Pfizer vaccine. He saw his ear, nose and throat doctor. His ENT doctor advised him surprisingly based on these other patients that came with same symptoms as him advised to skip the second vaccine. Patient didn't really want to skip the second dose, but he was at the 42 days and he want to wait for his tinnitus to get lower before getting it. Patient don't know what to do if he waited had 42 days there was no research, he would still like could get it his ears heel or if the tinnitus got lower. Patient had the severe tinnitus from the day he got the vaccine and he was now getting the 42 days maximum gap between doses. The patient underwent lab test and procedure which included Audiology for his hearing, was the one to check for his lost hearing: tinnitus from the vaccine on 24Mar2021. No treatment was received for the event. The outcome of the event was not recovered.  No follow-up attempts are needed. No further information is expected.
Age: 72.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Choking, Cough, Herpes zoster, Myalgia, Nasal congestion
Clinical narrative: Shingles; head cold; Congestion; mucus; muscle ache; This is a spontaneous report received from a contactable consumer (patient). A 72-year-old male patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE Solution for injection, lot number: EL9266), via an unspecified route of administration in the left arm, on 26Feb2021 09:00, as single dose, for COVID-19 immunisation. There were no medical history, known allergies and concomitant medications. Historical vaccine included the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EN9581) received at ate 72 years, via an unspecified route of administration in the left arm, on 29Jan2021 09:00, for COVID-19 immunisation. The were no other vaccines administered in 4 weeks and no other vaccine was administered on the same date as BNT162B2. On 03Mar2021 12:00, 5 days after the second vaccination, the patient was diagnosed with shingles. It was also reported that on an unspecified date in Mar2021, the patient developed have a very severe head cold, congestion, mucus, muscle ache, "etc" (pending clarification). All the events resulted to physician's office visit. Treatment for the event shingles included valacyclovir 1g. The outcome of the events was not resolved.
Age: 72.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Nasopharyngitis, Secretion discharge
Clinical narrative: Shingles; head cold; Congestion; mucus; muscle ache; This is a spontaneous report received from a contactable consumer (patient). A 72-year-old male patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE Solution for injection, lot number: EL9266), via an unspecified route of administration in the left arm, on 26Feb2021 09:00, as single dose, for COVID-19 immunisation. There were no medical history, known allergies and concomitant medications. Historical vaccine included the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EN9581) received at ate 72 years, via an unspecified route of administration in the left arm, on 29Jan2021 09:00, for COVID-19 immunisation. The were no other vaccines administered in 4 weeks and no other vaccine was administered on the same date as BNT162B2. On 03Mar2021 12:00, 5 days after the second vaccination, the patient was diagnosed with shingles. It was also reported that on an unspecified date in Mar2021, the patient developed have a very severe head cold, congestion, mucus, muscle ache, "etc" (pending clarification). All the events resulted to physician's office visit. Treatment for the event shingles included valacyclovir 1g. The outcome of the events was not resolved.
Age: 72.0
Sex: M
Vaccine: COVID19, COVID19, COVID19
Symptoms: Herpes zoster, Myalgia, Nasal congestion, Nasopharyngitis, Secretion discharge
Clinical narrative: Shingles; head cold; Congestion; mucus; muscle ache; This is a spontaneous report received from a contactable consumer (patient). A 72-year-old male patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE Solution for injection, lot number: EL9266), via an unspecified route of administration in the left arm, on 26Feb2021 09:00, as single dose, for COVID-19 immunisation. There were no medical history, known allergies and concomitant medications. Historical vaccine included the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EN9581) received at ate 72 years, via an unspecified route of administration in the left arm, on 29Jan2021 09:00, for COVID-19 immunisation. The were no other vaccines administered in 4 weeks and no other vaccine was administered on the same date as BNT162B2. On 03Mar2021 12:00, 5 days after the second vaccination, the patient was diagnosed with shingles. It was also reported that on an unspecified date in Mar2021, the patient developed have a very severe head cold, congestion, mucus, muscle ache, "etc" (pending clarification). All the events resulted to physician's office visit. Treatment for the event shingles included valacyclovir 1g. The outcome of the events was not resolved.
Age: 49.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Unevaluable event
Clinical narrative: Patient presented to the ED with bowel obstruction and was subsequently hospitalized within 6 weeks of receiving COVID vaccination.
Age: 49.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Intestinal obstruction
Clinical narrative: Patient presented to the ED with bowel obstruction and was subsequently hospitalized within 6 weeks of receiving COVID vaccination.
Age: 37.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Dysgeusia, Vaccination site pain
Clinical narrative: chills; fatigue; in bed most of the day (sleeping); This is a spontaneous report from a contactable consumer (patient). A 37-year-old male patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EL3247), intramuscularly on 17Mar2021 (at 37-year-old) at single dose for COVID-19 immunization. Medical history included asthma from 1990 and ongoing, ACL replacement surgery from 2001 to 2001. There were no concomitant medications. The patient previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EL3247), intramuscularly on 23Feb2021 (at 37-year-old) at single dose for COVID-19 immunization, experienced metallic taste in mouth and injection site pain. None prior vaccination within 4 weeks. On 18Mar2021, the day after dose 2, patient was in bed most of the day (sleeping) with chills and fatigue. By evening the patient was recovered. Seriousness criteria was reported as non serious. None relevant tests. No treatment was received for the events. The outcome of the events was recovered on 18Mar2021.  No follow-up attempts are possible. No further information is expected.
Age: 37.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Chills, Fatigue, Somnolence
Clinical narrative: chills; fatigue; in bed most of the day (sleeping); This is a spontaneous report from a contactable consumer (patient). A 37-year-old male patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EL3247), intramuscularly on 17Mar2021 (at 37-year-old) at single dose for COVID-19 immunization. Medical history included asthma from 1990 and ongoing, ACL replacement surgery from 2001 to 2001. There were no concomitant medications. The patient previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EL3247), intramuscularly on 23Feb2021 (at 37-year-old) at single dose for COVID-19 immunization, experienced metallic taste in mouth and injection site pain. None prior vaccination within 4 weeks. On 18Mar2021, the day after dose 2, patient was in bed most of the day (sleeping) with chills and fatigue. By evening the patient was recovered. Seriousness criteria was reported as non serious. None relevant tests. No treatment was received for the events. The outcome of the events was recovered on 18Mar2021.  No follow-up attempts are possible. No further information is expected.
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Pain, Pain in extremity
Clinical narrative: a bit more serious soreness; 99 degree fever lasting 24hrs; This is a spontaneous report from a contactable consumer (patient). A 69-year-old patient of an unspecified gender received second dose of bnt162b2 (Batch/Lot Number: EN6200), via an unspecified route of administration on 26Feb2021 as single dose for covid-19 immunization. The patient had no medical history. The patient had no concomitant drugs. The patient previous received first dose of bnt162b2 (Batch/Lot Number: E19265) on 05Feb2021 for covid-19 immunization and developed Minor soreness in arm. The patient experienced a bit more serious soreness, 99 degree fever lasting 24hrs on an unspecified date. The patient underwent lab tests and procedures which included covid-19: negative on 15Jan2021. The outcome of events was unknown. Vaccine administered at a facility: No. Prior vaccinations within 4 weeks was none.  No follow-up attempts are possible. No further information is expected.
Sex: U
Vaccine: COVID19, COVID19
Symptoms: Pain in extremity, Pyrexia, SARS-CoV-2 test
Clinical narrative: a bit more serious soreness; 99 degree fever lasting 24hrs; This is a spontaneous report from a contactable consumer (patient). A 69-year-old patient of an unspecified gender received second dose of bnt162b2 (Batch/Lot Number: EN6200), via an unspecified route of administration on 26Feb2021 as single dose for covid-19 immunization. The patient had no medical history. The patient had no concomitant drugs. The patient previous received first dose of bnt162b2 (Batch/Lot Number: E19265) on 05Feb2021 for covid-19 immunization and developed Minor soreness in arm. The patient experienced a bit more serious soreness, 99 degree fever lasting 24hrs on an unspecified date. The patient underwent lab tests and procedures which included covid-19: negative on 15Jan2021. The outcome of events was unknown. Vaccine administered at a facility: No. Prior vaccinations within 4 weeks was none.  No follow-up attempts are possible. No further information is expected.
Age: 37.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Ear pain, Facial pain, Paraesthesia
Clinical narrative: Tingly feeling on her left face; A ring sound on her left ear and pain as well; A ring sound on her left ear and pain as well; Pain in the injection area; This is a spontaneous report from a Pfizer sponsored program from a contactable consumer (patient). A 37-years-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), dose 1 via an unspecified route of administration on 01Apr2021 (Lot number was not reported) as SINGLE DOSE for covid-19 immunisation. The patient medical history was not reported. The patient's concomitant medications were not reported. The patient stated that she had a reaction after the 1st dose of the vaccine last 01Apr2021, pain in the injection area, tingly feeling on her left face, a ring sound on her left ear and pain as well. Now, she wants to know more about her reaction and if it is safe for her to get the 2nd dose of the vaccine on 22Apr2021. It is reported that she received the first dose of the Pfizer-BioNtech CoVid-19 vaccine on 01Apr2021, immediately after getting the shot, the left side of her face started tingling and it lasted for a couple hours. A couple days later her left ear started hurting and the pain has not gone away, she has like a ringing in her ear, her right ear is also experiencing some. Caller states she found that some people has even lost their hearing. She would like to know if she should procced with the second dose of the vaccine and if the ear problems are permanent and if the second dose of the vaccine will make the side-effects worse and if she should delay a couple weeks the second dose if that helps. The outcome of the event tingly feeling on her left face was recovered in Apr2021, the outcome of the event ear pain was not recovered, outcome of the remain events was unknown.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 37.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Ear pain, Paraesthesia, Tinnitus, Vaccination site pain
Clinical narrative: Tingly feeling on her left face; A ring sound on her left ear and pain as well; A ring sound on her left ear and pain as well; Pain in the injection area; This is a spontaneous report from a Pfizer sponsored program from a contactable consumer (patient). A 37-years-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), dose 1 via an unspecified route of administration on 01Apr2021 (Lot number was not reported) as SINGLE DOSE for covid-19 immunisation. The patient medical history was not reported. The patient's concomitant medications were not reported. The patient stated that she had a reaction after the 1st dose of the vaccine last 01Apr2021, pain in the injection area, tingly feeling on her left face, a ring sound on her left ear and pain as well. Now, she wants to know more about her reaction and if it is safe for her to get the 2nd dose of the vaccine on 22Apr2021. It is reported that she received the first dose of the Pfizer-BioNtech CoVid-19 vaccine on 01Apr2021, immediately after getting the shot, the left side of her face started tingling and it lasted for a couple hours. A couple days later her left ear started hurting and the pain has not gone away, she has like a ringing in her ear, her right ear is also experiencing some. Caller states she found that some people has even lost their hearing. She would like to know if she should procced with the second dose of the vaccine and if the ear problems are permanent and if the second dose of the vaccine will make the side-effects worse and if she should delay a couple weeks the second dose if that helps. The outcome of the event tingly feeling on her left face was recovered in Apr2021, the outcome of the event ear pain was not recovered, outcome of the remain events was unknown.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 16.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Product administered to patient of inappropriate age
Clinical narrative: Vaccine administered to person > 18yo. No other concerns, symptoms, signs, or otherwise were reported.
Age: 24.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Injection site erythema, Injection site induration, Injection site inflammation, Injection site pain, Injection site pruritus
Clinical narrative: Pt developed an injection site reaction that she described as an allergic rash: raised, itchy, red, and swollen.
Age: 24.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Injection site warmth
Clinical narrative: Pt developed an injection site reaction that she described as an allergic rash: raised, itchy, red, and swollen.
Age: 24.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Injection site erythema, Injection site pruritus, Injection site rash, Injection site swelling, Rash
Clinical narrative: Pt developed an injection site reaction that she described as an allergic rash: raised, itchy, red, and swollen.
Age: 24.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Rash papular
Clinical narrative: Pt developed an injection site reaction that she described as an allergic rash: raised, itchy, red, and swollen.
Age: 81.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Asthenia, Burning sensation, Dizziness, Ear pain, Gait disturbance
Clinical narrative: Deep vein thrombosis leg; This is a spontaneous report from a contactable consumer, based on information received by Pfizer. This case is split from master case for a 81 year old patient taking BNT162B2 and experienced Deep vein thrombosis leg.   This is a spontaneous report from a contactable consumer. An 81-years-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 09Mar2021 (Batch/Lot number was not reported) as single dose for covid-19 immunisation. Medical history included exposed to toxins from 911, patient stated that she is 911 survivor. The patient's concomitant medications were not reported. The patient experienced deep vein thrombosis leg on an unspecified date. The event outcome was unknown.
Age: 81.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Headache, Joint swelling, Nausea, Oral pain, Oropharyngeal pain
Clinical narrative: Deep vein thrombosis leg; This is a spontaneous report from a contactable consumer, based on information received by Pfizer. This case is split from master case for a 81 year old patient taking BNT162B2 and experienced Deep vein thrombosis leg.   This is a spontaneous report from a contactable consumer. An 81-years-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 09Mar2021 (Batch/Lot number was not reported) as single dose for covid-19 immunisation. Medical history included exposed to toxins from 911, patient stated that she is 911 survivor. The patient's concomitant medications were not reported. The patient experienced deep vein thrombosis leg on an unspecified date. The event outcome was unknown.
Age: 81.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Pain in extremity, Peripheral venous disease, Pyrexia, Rash, Somnolence
Clinical narrative: Deep vein thrombosis leg; This is a spontaneous report from a contactable consumer, based on information received by Pfizer. This case is split from master case for a 81 year old patient taking BNT162B2 and experienced Deep vein thrombosis leg.   This is a spontaneous report from a contactable consumer. An 81-years-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 09Mar2021 (Batch/Lot number was not reported) as single dose for covid-19 immunisation. Medical history included exposed to toxins from 911, patient stated that she is 911 survivor. The patient's concomitant medications were not reported. The patient experienced deep vein thrombosis leg on an unspecified date. The event outcome was unknown.
Age: 81.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Thrombosis, Ultrasound scan
Clinical narrative: Deep vein thrombosis leg; This is a spontaneous report from a contactable consumer, based on information received by Pfizer. This case is split from master case for a 81 year old patient taking BNT162B2 and experienced Deep vein thrombosis leg.   This is a spontaneous report from a contactable consumer. An 81-years-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 09Mar2021 (Batch/Lot number was not reported) as single dose for covid-19 immunisation. Medical history included exposed to toxins from 911, patient stated that she is 911 survivor. The patient's concomitant medications were not reported. The patient experienced deep vein thrombosis leg on an unspecified date. The event outcome was unknown.
Age: 81.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Lip pain, Lip swelling, Mouth cyst, Thrombosis, Visual impairment
Clinical narrative: Deep vein thrombosis leg; This is a spontaneous report from a contactable consumer, based on information received by Pfizer. This case is split from master case for a 81 year old patient taking BNT162B2 and experienced Deep vein thrombosis leg.   This is a spontaneous report from a contactable consumer. An 81-years-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 09Mar2021 (Batch/Lot number was not reported) as single dose for covid-19 immunisation. Medical history included exposed to toxins from 911, patient stated that she is 911 survivor. The patient's concomitant medications were not reported. The patient experienced deep vein thrombosis leg on an unspecified date. The event outcome was unknown.
Age: 81.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: X-ray
Clinical narrative: Deep vein thrombosis leg; This is a spontaneous report from a contactable consumer, based on information received by Pfizer. This case is split from master case for a 81 year old patient taking BNT162B2 and experienced Deep vein thrombosis leg.   This is a spontaneous report from a contactable consumer. An 81-years-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 09Mar2021 (Batch/Lot number was not reported) as single dose for covid-19 immunisation. Medical history included exposed to toxins from 911, patient stated that she is 911 survivor. The patient's concomitant medications were not reported. The patient experienced deep vein thrombosis leg on an unspecified date. The event outcome was unknown.
Age: 81.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Deep vein thrombosis
Clinical narrative: Deep vein thrombosis leg; This is a spontaneous report from a contactable consumer, based on information received by Pfizer. This case is split from master case for a 81 year old patient taking BNT162B2 and experienced Deep vein thrombosis leg.   This is a spontaneous report from a contactable consumer. An 81-years-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration on 09Mar2021 (Batch/Lot number was not reported) as single dose for covid-19 immunisation. Medical history included exposed to toxins from 911, patient stated that she is 911 survivor. The patient's concomitant medications were not reported. The patient experienced deep vein thrombosis leg on an unspecified date. The event outcome was unknown.
Age: 27.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Rash
Clinical narrative: So the first night, I had a fever, achy, near the injection site was warm and it hurt; stiffness there at the site  and headache- a lot of flu-like symptoms - it was about 36 hours that they lasted. Thursday evening, 8th, I got hives - all over my body and that started on my left arm and then it didn't go in my mouth but otherwise all over. I went to my doctor  - the ER at my doctor's site - on Saturday, 10th. He prescribed me some medicine - don't remember what plus I took Benadryl . I had to take a week and a half off of work because the medication was so strong.  My hives lasted another week. It stopped growing after that week and then it started healing.
Age: 27.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Headache, Impaired work ability, Influenza like illness, Injection site pain, Injection site warmth
Clinical narrative: So the first night, I had a fever, achy, near the injection site was warm and it hurt; stiffness there at the site  and headache- a lot of flu-like symptoms - it was about 36 hours that they lasted. Thursday evening, 8th, I got hives - all over my body and that started on my left arm and then it didn't go in my mouth but otherwise all over. I went to my doctor  - the ER at my doctor's site - on Saturday, 10th. He prescribed me some medicine - don't remember what plus I took Benadryl . I had to take a week and a half off of work because the medication was so strong.  My hives lasted another week. It stopped growing after that week and then it started healing.
Age: 27.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Musculoskeletal stiffness, Pain, Pyrexia, Urticaria
Clinical narrative: So the first night, I had a fever, achy, near the injection site was warm and it hurt; stiffness there at the site  and headache- a lot of flu-like symptoms - it was about 36 hours that they lasted. Thursday evening, 8th, I got hives - all over my body and that started on my left arm and then it didn't go in my mouth but otherwise all over. I went to my doctor  - the ER at my doctor's site - on Saturday, 10th. He prescribed me some medicine - don't remember what plus I took Benadryl . I had to take a week and a half off of work because the medication was so strong.  My hives lasted another week. It stopped growing after that week and then it started healing.
Age: 63.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Photopsia, Vision blurred, Vomiting
Clinical narrative: About an hours after vaccine I started seeing strobe lights and the next morning I couldn't see small print anymore. I went to the eye doctor.
Age: 63.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Ophthalmological examination, Visual impairment
Clinical narrative: About an hours after vaccine I started seeing strobe lights and the next morning I couldn't see small print anymore. I went to the eye doctor.
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Feeling hot, Hypoaesthesia oral, Paraesthesia
Clinical narrative: This is spontaneous report from contactable Nurse (patient) via Pfizer-sponsored program. A 65-years-old female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Lot number: unknown), via an unspecified route of administration in Apr2021 at single dose for COVID-19 immunization. Medical history and concomitant medications were not reported. Patient reported after receiving first dose, immediately had a "slight reaction". Patient reported to have her "body go hot, went down to the thigh, up until the head (not a fever) felt hot all over, woozy, and numbness at the roof of mouth. Patient estimated 93 minutes total time for the reaction, which could also be due to some anxiety as well. Patient stated had a side effect after the first dose of the vaccine. Patient asked should I get the second dose. She got a response as, vaccine if you had a severe allergic reaction after a previous dose of the vaccine or if you had a severe allergic reaction to any ingredient of the vaccine. The decision to receive the second dose for any other reason cannot be made by Pfizer. We refer you to speak to your healthcare provider about the risks of the vaccine compared to the risks of potentially not being fully protected against COVID-19 infection. Your healthcare provider knows your health situation and has access to information that can better help inform this decision. Patient was scheduled to receive her second dose on 05May2021. Patient was given Benadryl and then in a total time of 3 minutes all symptoms went away, Patient stated that she took an Ativan afterwards thinking possible anxiety from having the vaccine, patient was questioning if she should have second dose. There were unaddressed medical questions referred or forwarded to Medical Information. The outcome of the events was recovered. No follow-up attempts are needed. Information about lot/batch number cannot be obtained.
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Dizziness, Feeling hot, Hypoaesthesia oral
Clinical narrative: This is spontaneous report from contactable Nurse (patient) via Pfizer-sponsored program. A 65-years-old female patient received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Lot number: unknown), via an unspecified route of administration in Apr2021 at single dose for COVID-19 immunization. Medical history and concomitant medications were not reported. Patient reported after receiving first dose, immediately had a "slight reaction". Patient reported to have her "body go hot, went down to the thigh, up until the head (not a fever) felt hot all over, woozy, and numbness at the roof of mouth. Patient estimated 93 minutes total time for the reaction, which could also be due to some anxiety as well. Patient stated had a side effect after the first dose of the vaccine. Patient asked should I get the second dose. She got a response as, vaccine if you had a severe allergic reaction after a previous dose of the vaccine or if you had a severe allergic reaction to any ingredient of the vaccine. The decision to receive the second dose for any other reason cannot be made by Pfizer. We refer you to speak to your healthcare provider about the risks of the vaccine compared to the risks of potentially not being fully protected against COVID-19 infection. Your healthcare provider knows your health situation and has access to information that can better help inform this decision. Patient was scheduled to receive her second dose on 05May2021. Patient was given Benadryl and then in a total time of 3 minutes all symptoms went away, Patient stated that she took an Ativan afterwards thinking possible anxiety from having the vaccine, patient was questioning if she should have second dose. There were unaddressed medical questions referred or forwarded to Medical Information. The outcome of the events was recovered. No follow-up attempts are needed. Information about lot/batch number cannot be obtained.
Age: 16.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Syncope
Clinical narrative: Patient had a syncopal episode after receiving vaccine. Apparently there is a history of anxiety over needles per family on scene.
Age: 62.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Necrotising retinitis, Viral test
Clinical narrative: Acute retinal necrosis. Treated with valacyclovir, topical and oral steroids
Age: 62.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Biopsy, Necrotising retinitis, Treponema test positive, Varicella virus test positive, Varicella zoster virus infection
Clinical narrative: Acute retinal necrosis. Treated with valacyclovir, topical and oral steroids
Age: 61.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Abdominal pain upper, Asthenia, Confusional state, Diarrhoea, Dizziness
Clinical narrative: This is a spontaneous report from a contactable consumer (patient). This is the second report for 1st dose of BNT162B2. A 61 years-old female patient received 1st dose of BNT162B2 (Covid vaccine, Expiry Date: 31May2021, lot#EN9581) on 17Feb2021 at single dose for covid-19 immunization. Medical history and concomitant drug were not reported. Consumer stated, "I had severe reaction to COVID vaccine and I want to report that (Refer to AER#2021439636 for 2nd dose). Consumer stated, "I had reaction after the first one but I want to say 13 days later I started feeling sick and I wholly got sick. Outcome of the event was unknown. No follow-up attempts are needed. No further information is expected.; Sender's Comments: Linked Report(s) : US-PFIZER INC-2021439636 same patient/reporter/drug in separate time.